Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Treatment of refractory multiple myeloma and considerations for future therapy.

Kyle RA, Greipp PR, Gertz MA.

Semin Oncol. 1986 Sep;13(3):326-33. Review. No abstract available.

PMID:
3532331
2.

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

Barlogie B, Smith L, Alexanian R.

N Engl J Med. 1984 May 24;310(21):1353-6.

PMID:
6546971
3.

VAD followed by VMCP: an alternative regimen for multiple myeloma.

Wadhwa J, Kumar L, Kochupillai V.

Med Oncol. 2002;19(2):105-8.

PMID:
12180477
4.

Cross-resistance to alkylating agents in multiple myeloma.

Bladé J, Feliú E, Rozman C, Estapé J, Millá A, Montserrat E.

Cancer. 1983 Sep 1;52(5):786-9.

5.

Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

Steinke B, Busch FW, Becherer C, Ostendorf P, Waller HD.

Cancer Chemother Pharmacol. 1985;14(3):279-81.

PMID:
3838922
6.

Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.

Van Dobbenburgh OA, Houwen B, Piersma H, Marrink J, Ockhuizen T, Halie MR, Nieweg HO.

Neth J Med. 1984;27(2):25-30. No abstract available.

PMID:
6709108
7.

Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.

Buonanno G, Tortarolo M, Valente A, Castaldo C, Russolillo S, Gonnella F.

Haematologica. 1978 Feb;63(1):45-55. No abstract available.

PMID:
417971
8.

[Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].

Monconduit M, Le Loët X, Bernard JF, Menard JF, Grosbois B, Michaux JL, De Gramont A, Laporte JP, Najman A, Jouet JP, et al.

Rev Rhum Mal Osteoartic. 1987 Jun;54(6):477-9. French. No abstract available.

PMID:
3616472
9.

Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.

Alberts DS, Salmon SE.

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):345-50.

PMID:
1097093
10.

[Recent therapy for refractory myeloma].

Togawa A.

Rinsho Ketsueki. 1993 Apr;34(4):450-4. Japanese.

PMID:
8510332
11.

Alternating combination chemotherapy does not delay development of refractoriness in myeloma.

Osby E, Beksac M, Reizenstein P.

Anticancer Res. 1986 Sep-Oct;6(5):1145-7.

PMID:
3800322
12.

[Combined cytostatic therapy of plasmacytoma].

Albert P, Zsuzsa M.

Orv Hetil. 1977 Jul 31;118(31):1855-6. Hungarian. No abstract available.

PMID:
887257
13.

[Chemotherapy of multiple myeloma].

Estape J, Antón I, Daniels M, Bladé J, Domingo A, Rubio D.

Sangre (Barc). 1984;29(5):936-9. Spanish. No abstract available.

PMID:
6523344
14.

Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma.

Ohrling M, Björkholm M, Osterborg A, Juliusson G, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, et al.

Eur J Haematol. 1993 Jul;51(1):45-9.

PMID:
8348944
15.

Chemotherapy for multiple myeloma.

Alexanian R, Dreicer R.

Cancer. 1984 Feb 1;53(3):583-8.

16.

Vindesine in refractory multiple myeloma.

van der Lelie H, Monasch E, Pegels HG, von dem Borne AE.

Cancer. 1986 Jan 15;57(2):226-9.

17.

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.

Haematologica. 2006 May;91(5):621-7. Epub 2006 Apr 19.

18.

Diagnosis and management of multiple myeloma.

UK myeloma forum. British Committee for Standards in Haematology..

Br J Haematol. 2001 Dec;115(3):522-40. No abstract available.

PMID:
11736932
19.

Prednisone pulse therapy for refractory myeloma.

Alexanian R, Yap BS, Bodey GP.

Blood. 1983 Sep;62(3):572-7.

20.

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

Crowley J, Jacobson J, Alexanian R.

Semin Hematol. 2001 Jul;38(3):203-8. Review.

PMID:
11486307

Supplemental Content

Support Center